NT_1170x120_1-11-18

AbbVie

AbbVie to acquire Allergan

AbbVie to acquire Allergan

NORTH CHICAGO, Ill. — AbbVie  and Allergan announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie’s common stock of $78.45 on June 24, 2019. (PRNewsfoto/AbbVie) “This is a

AbbVie donates $100 mil. for health care, housing in Puerto Rico

AbbVie donates $100 mil. for health care, housing in Puerto Rico

NORTH CHICAGO, Ill. — AbbVie announced a donation of $100 million to two organizations, Direct Relief and Habitat for Humanity International, to strengthen access to healthcare and housing in Puerto Rico. The organizations will receive $50 million each. This donation is an extension of the more than $4 million AbbVie provided following the unprecedented natural disasters of 2017. “AbbVie has a longstanding commitment

WBA hires AbbVie VP to lead USA communications

WBA hires AbbVie VP to lead USA communications

DEERFIELD, Ill. — Gulden Mesara-Dogan has joined Walgreens Boots Alliance (WBA) as vice president of communications USA, the division that includes the Walgreens and Duane Reade drug chains. In the role, Mesara-Dogan will oversee communications serving WBA’s enterprise and USA businesses and operations, including the Walgreens communications division, Walgreens external communications, and the WBA internal communications and

Boehringer Ingelheim biosimilar Cyltezo OK’d by FDA

Boehringer Ingelheim biosimilar Cyltezo OK’d by FDA

RIDGEFIELD, Conn. —  Boehringer Ingelheim Pharmaceuticals Inc. has gained Food and Drug Administration approval for Cyltezo, a biosimilar of Humira from AbbVie Inc. Boehringer Ingelheim said Tuesday that Cyltezo (adalimumab-adbm) comes in a prefilled syringe and is indicated to treat a range of chronic inflammatory diseases, including moderate to severe active rheumatoid arthritis, moderate to

Par Pharmaceutical ships AndroGel generic

Par Pharmaceutical ships AndroGel generic

CHESTNUT RIDGE, N.Y. — Par Pharmaceutical has released testosterone gel 1%, a generic version of AndroGel 1% from AbbVie. Par said Wednesday that its testosterone gel 1% product is available in 2.5g and 5g aluminum foil packets containing 25 mg or 50 mg of testosterone, respectively. The company noted that it previously entered into a

CVS strikes deal with Gilead

WOONSOCKET, R.I. — CVS Health and Gilead Sciences have reached a deal to make Gilead’s hepatitis C drugs, Harvoni and Sovaldi, the exclusive option for patients on its commercial drug list, as well as for those it manages on health care exchanges, Medicare Part D and Medicaid. The move partly counteracts a recent decision by